Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Cassava Sciences Inc (FLNA) vs Vanguard Short Term Corporate Bond ETF (VCSH) Price & Performance

Cassava Sciences IncTrade
Vanguard Short Term Corporate Bond ETFTrade

Price performance (Past 24H)

Key statistics

Cassava Sciences Inc vs Vanguard Short Term Corporate Bond ETF — how do they compare? Cassava Sciences Inc trades at $0.95 (market cap $47.75M), while Vanguard Short Term Corporate Bond ETF trades at $78.61. Which is the better fit depends on your goals.

FLNAVCSH
Market Cap
$47.75M
Sector
HealthFixed Income
52-Week High
$4.64$80.20
52-Week Low
$0.87$78.41
Enterprise Value
-$34.93M

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Cassava Sciences Inc

FLNA trades at $0.9528, down 4.46% today, with a bearish technical outlook but strong analyst support (66.7% buy ratings). The company continues to post net losses and negative cash flows, though recent EPS beats show some operational improvement. Recent news highlights Q2 2026 results and business updates on Tuberous Sclerosis Complex therapies.

The outlook remains speculative due to persistent unprofitability and cash burn, but analyst optimism and a low P/B ratio of 0.75 may attract value investors. Key risks include execution challenges in drug development and reliance on financing amid negative earnings.

Vanguard Short Term Corporate Bond ETF

VCSH trades at $78.615, up 0.16% with a bearish technical outlook as moving averages signal selling pressure while oscillators remain neutral. The ETF maintains a 4.77% yield with short 2.7-year duration, though recent analysis suggests limited upside due to tight credit spreads. Recent institutional activity shows mixed positioning with Apella Capital reducing holdings while Bessemer Group and Allspring increased stakes significantly.

The outlook remains cautious with downgrades to 'Hold' citing unattractive entry points, though the short duration provides downside protection. Key risks include credit spread widening and Fed policy uncertainty, while the primary opportunity lies in stable income generation for conservative investors seeking corporate bond exposure.

Returns comparison

Trailing returns across standard periods

About Cassava Sciences Inc

Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease

Read more on FLNA

About Vanguard Short Term Corporate Bond ETF

VCSH tracks the Bloomberg U.S. 1-5 Year Corporate Bond Index, focusing on high-quality, investment-grade debt with short maturities. It is designed to offer higher income than Treasury bills with significantly lower interest rate sensitivity than intermediate or long-term bond funds.

Read more on VCSH